RE:Last day for tax-loss selling is today!What would happen to the current deal if one of our partners decided to move forward with one of the assets, ie Janssen, Chiesi, Prothena, Neuramedy, etc. At the value Bioasis is being given away for in the proposed buyout/takeover, it would seem that any progress on these licensing deals would drastically change the inherent value of Bioasis, and thus would trigger a revaluation of Bioasis, or presumably make such a deal unnecessary. If the negotiations of this buyout have been ongoing since mid year or longer, is it possible that potential deals are being held back or downplayed until this closes? I would assume there are some competing interests among the stakeholders if not outright conflict of interests…
“2) 23 business days until the expiration of the J&J multi-product option for xB3.” -POF
What if Janssen decides to move forward with further evaluation in the next month, as POF states, this is due to expire shortly, before the vote on this current deal I would assume. Will we hear if Janssen gives a thumbs up or thumbs down. Seems to me this, and other outstanding license deals would be materially relevant to this company’s future and its need for a death spiral financing/acquisition.
And then there is XB3-001, what about that asset, what about the license to Ellipses which was selectively disclosed to certain parties? I assume a successful license or sale of such asset would be a material development that should be disclosed to all parties, not just to a select audience who happened to attend a road show. Why does it not appear on any corporate material now? It this deal done and not announced, did it fall apart, or was this phrase that appeared on a corporate presentation and typo?
So many questions with no clear answers from where I sit.